MX2015013186A - Adminitracion craneal de productos farmaceuticos. - Google Patents
Adminitracion craneal de productos farmaceuticos.Info
- Publication number
- MX2015013186A MX2015013186A MX2015013186A MX2015013186A MX2015013186A MX 2015013186 A MX2015013186 A MX 2015013186A MX 2015013186 A MX2015013186 A MX 2015013186A MX 2015013186 A MX2015013186 A MX 2015013186A MX 2015013186 A MX2015013186 A MX 2015013186A
- Authority
- MX
- Mexico
- Prior art keywords
- cranial
- adminitration
- pharmaceutical products
- disease
- condition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361790120P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/027280 WO2014152385A2 (en) | 2013-03-15 | 2014-03-14 | Cranial delivery of pharmaceuticals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015013186A true MX2015013186A (es) | 2016-04-15 |
Family
ID=51581702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015013186A MX2015013186A (es) | 2013-03-15 | 2014-03-14 | Adminitracion craneal de productos farmaceuticos. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9682032B2 (enExample) |
| EP (1) | EP2968368B1 (enExample) |
| JP (1) | JP6317805B2 (enExample) |
| CN (1) | CN105188708B (enExample) |
| AU (1) | AU2014239842B2 (enExample) |
| BR (1) | BR112015023694B1 (enExample) |
| CA (1) | CA2909490C (enExample) |
| ES (1) | ES2649730T3 (enExample) |
| HU (1) | HUE034886T2 (enExample) |
| MX (1) | MX2015013186A (enExample) |
| PT (1) | PT2968368T (enExample) |
| TW (1) | TWI636785B (enExample) |
| WO (1) | WO2014152385A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107106542B (zh) | 2014-10-20 | 2020-05-08 | 奥伊斯特普安生物制药公司 | 治疗眼部病状的方法 |
| US10456435B2 (en) | 2015-07-15 | 2019-10-29 | Christopher A. MCELVANY | Topical antiviral formulations and methods of using the same |
| EP3509585B1 (en) * | 2016-09-07 | 2023-11-01 | Glia, LLC | Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves |
| WO2020014072A1 (en) * | 2018-07-09 | 2020-01-16 | Gt Biopharma, Inc. | Neostigmine pharmaceutical combination for treating myasthenia gravis |
| CN109172580B (zh) * | 2018-09-06 | 2021-04-27 | 中山万汉制药有限公司 | 包含前列腺素衍生物的组合物以及包含该组合物的眼用液体制剂 |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| US12472158B2 (en) | 2019-02-27 | 2025-11-18 | Vanderbilt University | Methods of treating trigeminal nerve pain |
| US20230091716A1 (en) * | 2020-02-12 | 2023-03-23 | Glia, Llc | Progesterone Combinations |
| WO2023200906A1 (en) | 2022-04-12 | 2023-10-19 | Shackelford Pharma Inc. | Treatment of seizure disorders |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1071419B1 (en) * | 1998-04-21 | 2007-07-25 | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Cannabinoids as antioxidants and neuroprotectants |
| US6610674B1 (en) | 1999-09-28 | 2003-08-26 | University Of Pennsylvania | Method of treating inflammatory conditions with progesterone analogs |
| US8449908B2 (en) | 2000-12-22 | 2013-05-28 | Alltranz, Llc | Transdermal delivery of cannabidiol |
| US20040037895A1 (en) | 2002-08-23 | 2004-02-26 | Alex Zhu | Methods of treating involuntary facial spasms and facial wrinkles |
| US20060089408A1 (en) | 2004-10-22 | 2006-04-27 | Wei Ted C Jr | Method of treating blepharospasm with a prostaglandin derivative |
| US20080132475A1 (en) * | 2006-12-05 | 2008-06-05 | Charles Gerald Connor | Treatment for dry eye |
| US8222292B2 (en) * | 2007-08-06 | 2012-07-17 | Insys Therapeutics, Inc. | Liquid cannabinoid formulations |
| US7632868B2 (en) | 2007-10-31 | 2009-12-15 | Meta Cosmetics, Llc | Prostaglandin analog compositions to treat epithelial-related conditions |
| US20100016264A1 (en) * | 2007-12-05 | 2010-01-21 | Connor Charles G | Treatment for dry eye using testosterone and progestagen |
| US8236768B2 (en) | 2008-10-03 | 2012-08-07 | 3B Pharmaceuticals, Inc. | Topical antiviral formulations |
| WO2011055383A2 (en) | 2009-11-06 | 2011-05-12 | Lyka Labs Limited | Intranasal delivery to improve the performance of children suffering from dyslexia |
| US9439875B2 (en) | 2011-05-11 | 2016-09-13 | The United States Of America, As Represented By The Secretary Of Agriculture | Anxiolytic effect of pterostilbene |
| WO2014018856A1 (en) | 2012-07-27 | 2014-01-30 | Rhodes Technologies | Compositions and treatment for eye diseases and disorders |
-
2014
- 2014-03-14 EP EP14768223.1A patent/EP2968368B1/en active Active
- 2014-03-14 CN CN201480024402.3A patent/CN105188708B/zh active Active
- 2014-03-14 HU HUE14768223A patent/HUE034886T2/hu unknown
- 2014-03-14 PT PT147682231T patent/PT2968368T/pt unknown
- 2014-03-14 AU AU2014239842A patent/AU2014239842B2/en active Active
- 2014-03-14 TW TW103109706A patent/TWI636785B/zh active
- 2014-03-14 US US14/777,278 patent/US9682032B2/en active Active
- 2014-03-14 ES ES14768223.1T patent/ES2649730T3/es active Active
- 2014-03-14 BR BR112015023694-4A patent/BR112015023694B1/pt active IP Right Grant
- 2014-03-14 WO PCT/US2014/027280 patent/WO2014152385A2/en not_active Ceased
- 2014-03-14 JP JP2016502396A patent/JP6317805B2/ja active Active
- 2014-03-14 MX MX2015013186A patent/MX2015013186A/es active IP Right Grant
- 2014-03-14 CA CA2909490A patent/CA2909490C/en active Active
-
2017
- 2017-06-20 US US15/627,894 patent/US10251835B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TW201513867A (zh) | 2015-04-16 |
| AU2014239842B2 (en) | 2018-07-19 |
| CA2909490C (en) | 2021-07-13 |
| CA2909490A1 (en) | 2014-09-25 |
| EP2968368B1 (en) | 2017-08-09 |
| EP2968368A4 (en) | 2016-10-12 |
| CN105188708B (zh) | 2019-06-28 |
| HUE034886T2 (hu) | 2018-03-28 |
| BR112015023694B1 (pt) | 2021-05-25 |
| ES2649730T3 (es) | 2018-01-15 |
| WO2014152385A3 (en) | 2014-12-11 |
| US20170281531A1 (en) | 2017-10-05 |
| WO2014152385A2 (en) | 2014-09-25 |
| PT2968368T (pt) | 2017-11-15 |
| EP2968368A2 (en) | 2016-01-20 |
| TWI636785B (zh) | 2018-10-01 |
| US20160030333A1 (en) | 2016-02-04 |
| BR112015023694A2 (pt) | 2017-07-18 |
| HK1213202A1 (zh) | 2016-06-30 |
| AU2014239842A1 (en) | 2015-11-05 |
| CN105188708A (zh) | 2015-12-23 |
| US9682032B2 (en) | 2017-06-20 |
| JP2016513691A (ja) | 2016-05-16 |
| JP6317805B2 (ja) | 2018-04-25 |
| US10251835B2 (en) | 2019-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX365939B (es) | Moduladores del transporte nuclear y usos de los mismos. | |
| MX2016000271A (es) | Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r. | |
| EA201591612A1 (ru) | ПРИМЕНЕНИЕ ПИРАЗОЛПИРИМИДИНОВЫХ ПРОИЗВОДНЫХ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, СВЯЗАННЫХ С PI3Kδ | |
| BR112015022197A2 (pt) | tratamento de cataplexia | |
| CL2017002242A1 (es) | Método para tratar un tumor cerebral | |
| NZ702663A (en) | Nuclear transport modulators and uses thereof | |
| WO2014152385A3 (en) | Cranial delivery of pharmaceuticals | |
| MX390084B (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
| NI201400112A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
| CR20150637A (es) | Tratamiento de enfermedades miopaticas y neurodegenerativas por agregación de proteina mediante administración parenteral | |
| PE20151526A1 (es) | Tratamiento de formas progresivas de esclerosis multiple con laquinimod | |
| NZ722600A (en) | Methods of treating mild brain injury | |
| EA201591434A1 (ru) | Способ обеспечения глазной нейропротекции | |
| MX2016002307A (es) | Tratamiento para el cancer. | |
| MX2016002308A (es) | Tratamiento del mieloma multiple. | |
| AR099416A1 (es) | Terapia combinada para la hipertensión resistente | |
| MX366309B (es) | Composicion farmaceutica para el tratamiento de inflamacion y dolor. | |
| ES2721003T3 (es) | Utilización de ácido 1, 3 - propano disulfónico o sales farmacéuticamente aceptables del mismo para el tratamiento de la sarcoidosis | |
| MY198753A (en) | Treatment of androgen deprivation therapy associated symptoms | |
| MX368640B (es) | Composición farmacéutica para tratar inflamación y dolor. | |
| MX368641B (es) | Compuestos para el tratamiento de inflamación y dolor. | |
| EA201690170A1 (ru) | Композиции и способы для лечения инсульта | |
| NZ715554A (en) | Method of treating hypertrophic cardiomyopathy | |
| MX2016002139A (es) | Composicion farmaceutica y uso del (2-cianoetil)fosfonato de dietilo. | |
| MX2016010919A (es) | 4-bencilsulfonil-2-butenonitrilo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |